Notably, our results not only disagree with an increased expression of SELENOP in PAH, they rather indicate an inverse relation, i.e., decreasing SELENOP levels with aggravated disease states and a potential loss of SELENOP-related protection against oxidative stress in SSc that may contribute to PAH progression [57]. This evidence concerns the gene SELENOP and systemic sclerosis.